Free tool
FAERS Monitor: Verquvo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214377 or its brand name (Verquvo, Vericiguat). Reports on generic versions are filed under their own applications.
Reports
994
Serious
510
51% of reports
Hospitalization
259
Death reported
152
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hypotension116
- death98
- cardiac failure77
- dizziness69
- product dose omission issue55
- no adverse event49
- blood pressure decreased43
- anaemia40
- fatigue37
- dyspnoea36
- malaise34
- nausea31
- product use issue30
- asthenia29
- diarrhoea29
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 2 |
| 2018 | 3 |
| 2021 | 114 |
| 2022 | 218 |
| 2023 | 213 |
| 2024 | 177 |
| 2025 | 181 |
| 2026 | 86 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,165 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cardiac failureSignal | 77 | 20.3 | 16.4 | 1,399 |
| blood pressure decreasedSignal | 43 | 13.7 | 10.2 | 495 |
| hypotensionSignal | 116 | 12.2 | 10.3 | 1,197 |
| no adverse eventSignal | 49 | 5.7 | 4.4 | 188 |
| anaemiaSignal | 40 | 4.4 | 3.3 | 104 |
| product dose omission issueSignal | 55 | 4.0 | 3.1 | 120 |
| product use issueSignal | 30 | 3.4 | 2.4 | 48 |
| dizzinessSignal | 69 | 2.9 | 2.3 | 88 |
| deathSignal | 98 | 2.4 | 2.0 | 83 |
| malaise | 34 | 1.6 | 1.2 | 8 |
| asthenia | 29 | 1.6 | 1.1 | 7 |
| dyspnoea | 36 | 1.3 | 1.0 | 3 |
| fatigue | 37 | 1.0 | 0.7 | 0 |
| diarrhoea | 29 | 1.0 | 0.7 | 0 |
| nausea | 31 | 0.8 | 0.6 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.